Company Quick10K Filing
Blake Insomnia Therapeutics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 2 $4
10-Q 2019-07-15 Quarter: 2019-05-31
10-Q 2019-04-23 Quarter: 2019-02-28
10-Q 2019-02-27 Quarter: 2018-11-30
10-K 2019-02-20 Annual: 2018-08-31
10-Q 2018-07-16 Quarter: 2018-05-31
10-Q 2018-06-07 Quarter: 2018-02-28
10-Q 2018-06-07 Quarter: 2017-11-30
10-K 2018-04-26 Annual: 2017-08-31
10-Q 2017-07-17 Quarter: 2017-05-31
10-Q 2017-04-18 Quarter: 2017-02-28
10-Q 2017-01-18 Quarter: 2016-11-30
10-K 2016-12-07 Annual: 2016-08-31
10-Q 2016-08-17 Quarter: 2016-05-31
10-Q 2016-04-20 Quarter: 2016-02-29
10-Q 2016-01-14 Quarter: 2015-11-30
10-K 2015-12-15 Annual: 2015-08-31
10-Q 2015-07-15 Quarter: 2015-05-31
10-Q 2015-04-20 Quarter: 2015-02-28
10-Q 2015-01-26 Quarter: 2014-11-30
10-K 2014-12-19 Annual: 2014-08-31
10-Q 2014-08-12 Quarter: 2014-05-31
10-Q 2014-04-30 Quarter: 2014-02-28
10-Q 2014-01-14 Quarter: 2013-11-30
10-K 2013-12-18 Annual: 2013-08-31
10-Q 2013-08-16 Quarter: 2013-05-31
8-K 2019-07-08 Enter Agreement, Sale of Shares, Regulation FD, Exhibits
8-K 2019-05-17 Control, Officers, Exhibits
8-K 2019-05-07 Other Events
8-K 2018-02-01 Enter Agreement, Officers, Exhibits

Blake Insomnia Therapeutics Financials

BKIT Metrics, Comps, Filings

Annual | Quarterly

Business

We are a New York-based pharmaceutical company devoted to improving nighttime and daytime quality of life for people with insomnia. We have developed Zleepax, which is the first sleep aid with beta blockers as the major active agent.

First generation beta blockers inhibited natural melatonin secretion and had a negative impact on sleep. Recent publications have shown that certain third-generation beta blockers actually improve quality of sleep for patients with mild hypertension. These third-generation beta blockers has been widely used to treat hypertension since the early 1990s, is well tolerated in chronic use, has an attractive side-effect profile, and should thus perform excellently applied as a sleep enhancer. Our patent application covers the use of beta blockers-alone or in combination with other anti-insomnia drugs-for the treatment of stress-related insomnia.

We have assembled a team to conduct clinical trials of our Zleepax formula. We have entered into a joint venture with Sajo Consulting LLC for development and commercialization efforts associated with our drug. Canadian clinical trials were originally planned for Q3 2017 pending approval of a New Drug Submission by the Health Products and Food Branch of Health Canada. However, we have been unable to raise funds necessary to commence the trials.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Oculus (OVTZ) 5,362 -19.3 -62% 414 137 0 0 -257 -257 4,949
Propanc Biopharma (PPCB) 983 -1.0 -2,593% 198 4,739 0 -24 -5,125 -3,561 3,434
Creative Learning (CLCN) 3,848 0% 2.2 61% 2,700 5,017 4,008 0 1,644 1,644 3,559
Nuo Therapeutics (AURX) 3,796 69% -2.2 -1,173% 154 1,347 344 236 -1,810 -1,734 3,787
Patriot Gold (PGOL) 4,463 0% 25.7 9% 1,935 226 436 0 166 166 4,261
Encision (ECIA) 3,709 51% -115.6 -4% 4,148 1,933 8,055 4,147 -152 -31 3,568
Innovus Pharmaceuticals (INNV) 5,796 65% -2.1 -63% 9,514 11,510 17,966 11,617 -5,984 -3,875 8,027
Blake Insomnia Therapeutics (BKIT) 3,681 -135.2 0 237 0 0 -27 -27 3,681
Geospatial (GSPH) 3,709 70% -6.3 -736% 111 3,656 273 190 -816 -586 3,668
Visium Technologies (VISM) 0 0.0 -31,116% 3 3,141 0 0 -796 -796 -3
Cartesian (CRTN) 3,632 30% -0.4 -44% 16,522 17,461 47,555 14,053 -7,270 -5,582 2,087
GraniteShares Platinum Trust (PLTM) 5,316 12.8 7% 5,803 2 0 0 415 415 5,316
Invesco CurrencyShares Singapore Dollar Trust (FXSG) 3,628 0% -50.4 1% 3,558 1 40 0 26 26 -1,288
Fieldpoint Petroleum (FPP) 3,628 0% 13.8 -5% 4,528 6,259 1,668 0 -241 247 3,414
American Church Mortgage (ACMC) 3,339 2.4 -0% 39,246 28,836 0 0 -48 1,343 3,218
Immune Pharmaceuticals (IMNP) 3,597 -0.9 -71% 20,716 19,874 0 0 -14,715 -13,953 12,494
American Bio Medica (ABMC) 3,580 35% -28.9 -20% 2,246 2,809 2,776 971 -440 -177 5,119
Empire Petroleum (EMPR) 3,576 0% -3.0 -30% 11,795 13,670 4,941 0 -3,541 -3,815 11,553
Genesis Financial (GFNL) 3,571 0% -1.1 -155% 2,427 3,394 10 0 -3,756 -3,242 3,551
Frontier Oilfield Services (FOSI) 3,542 0% -5.7 -319% 868 11,161 646 0 -2,768 -2,021 11,479

Balance Sheet ($'000)2013-08-312014-08-312015-08-312016-08-312017-08-312018-08-31
Cash2210500
Accounts Receivable
Inventory
PP&E
Assets2210500
Accounts Payable410112131
Long-Term Debt
Liabilities095386192236
Stockholders' Equity2-7-43-81-191-236
Income Statement ($'000)2013-08-312014-08-312015-08-312016-08-312017-08-312018-08-31
Revenue000000
Cost of Revenue0
Gross Profit0
R&D
SG&A
Tax000000
Net Income-9-220-36-38-110-45
Cash Flow ($'000)2013-08-312014-08-312015-08-312016-08-312017-08-312018-08-31
Cash Operating-9-5-20-32-77-0
Cash Investing00
Cash Financing1152827720